Senegal vs Serbia: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Senegal
91.0%
in 2025
Serbia
91.0%
in 2025
Senegal rank
59th
Serbia rank
59th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Senegal
- Serbia
How they compare
Senegal currently reports 91.0% against 91.0% in Serbia, a difference of 0.0%.
The two have swapped places 4 times across 18 shared years of data; in 2008 it was Serbia ahead.
Senegal ranks 59th and Serbia ranks 59th of 192 countries.
Senegal has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Senegal | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 53.8% | 15.9% | 37.9% | Senegal |
| 2020s | 88.5% | 87.5% | 1.0% | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Senegal or Serbia?
- Senegal, at 91.0% against 91.0% in Serbia as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Senegal and Serbia?
- 0.0%, with Senegal ahead.
- How many years of comparable data are there for Senegal and Serbia?
- 18 years are reported by both, from 2008 to 2025.
- How do Senegal and Serbia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Senegal ranks 59th and Serbia ranks 59th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.